AVRO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVRO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Avrobio has the GF Value Rank of 0.
The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of Avrobio's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Azadeh Golipour | officer: Chief Technology Officer | ONE KENDALL SQUARE, BLD. 300 - SUITE 201, CAMBRIDGE MA 02139 |
Essra Ridha | officer: Chief Medical Officer | C/O AVROBIO, INC., ONE KENDALL SQUARE, BLDG 300 - SUITE 201, CAMBRIDGE MA 02139 |
Philip J. Vickers | director | C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560 |
Christopher Mason | officer: Chief Scientific Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Phillip B. Donenberg | director | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
Diana Escolar | officer: Chief Medical Officer | C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301 |
Gail M Farfel | director | 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510 |
Deanna M Petersen | officer: Chief Business Officer | 45 FIRST AVENUE, WALTHAM MA 02451 |
Geoffrey Mackay | director, officer: See Remarks | C/O AVROBIO, INC., ONE KENDALL SQ, BLDG. 300, STE. 201, CAMBRIDGE MA 02139 |
Christopher Paige | director | C/O AVROBIO INC, ONE KENDALL SQ, BLDG 300, STE 201, CAMBRIDGE MA 02139 |
Atlas Venture Fund X, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates Opportunity I, Llc | other: See Remarks | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates Opportunity I, L.p. | other: See Remarks | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Opportunity Fund I, L.p. | other: See Remarks | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Bruce Booth | director | 890 WINTER STREET, SUITE 320, WALTHAM MA 02451 |
From GuruFocus
By Business Wire Business Wire • 05-16-2022
By Business Wire Business Wire • 05-17-2022
By Business Wire Business Wire • 10-18-2022
By Business Wire Business Wire • 07-13-2022
By Business Wire Business Wire • 08-31-2022
By Business Wire Business Wire • 02-09-2023
By Business Wire Business Wire • 05-10-2022
By Business Wire Business Wire • 08-01-2022
By Business Wire Business Wire • 05-11-2023
By Business Wire Business Wire • 10-25-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.